linjc16/ctgov huggingface dataset:
Assessment of Competence in Colonoscopy Using Motion Capture

Study Overview
=================
Brief Summary
-----------------
Aim: To study the basic technical skills of colonoscopy using a MS Kinect for motion analysis. In order to develop a non-biased tool to monitor competence.

Detailed Description
-----------------
To compare a group of novices to a group of experienced endoscopists performining colonoscopy. Analyzing the motion pattern of the performers using a Kinect. Use the contrasting group method to set standards.

Official Title
-----------------
Assessment of Competence in Colonoscopy Using Motion Capture

Conditions
-----------------
Sensitivity Training Groups

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: none experience in colonoscopy or experience more than 350 colonoscopy procedures - Exclusion Criteria: none -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| novices<br>novice endoscopists, fellows of gastroenterology | |
| experienced endoscopist<br>consultant doctors of gastroenterology | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to identify metrics of importans in colonoscopy training program | testing colonoscopy competence in a simulation lab. Finding metrics with discriminatory ability. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
simulation, training, colonoscopy, standard setting
Analgesic Efficacy of High Frequency Spinal Cord Stimulation

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare the efficacy of high frequency (HF SCS) stimulation and sham stimulation (Sham SCS - i.e. no stimulation) and conventional spinal cord stimulation (Conv SCS) on the patient reported global impression of change, pain intensity and health related quality of life.

Official Title
-----------------
Analgesic Efficacy of High Frequency Spinal Cord Stimulation: a Placebo-controlled Study

Conditions
-----------------
Lowback and Leg Pain

Intervention / Treatment
-----------------
* Device: High frequency spinal cord stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed informed consent treated with spinal cord stimulation stable pain relief achieved Exclusion Criteria: failure to give informed consent unable to use or understand how to handle the equipment, PGIC,VAS score or EQ-5D questionnaires.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Sequence 1<br>Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks) | Device: High frequency spinal cord stimulation<br> <br> |
| Other: Sequence 2<br>Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks) | Device: High frequency spinal cord stimulation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient's Global Impression of Change (PGIC) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of Pain |  |  | 
| Quality of Life (EQ-5D) |  |  |
Human Phototoxicity Test

Study Overview
=================
Brief Summary
-----------------
To determine the phototoxic potential of a topically applied article in human subjects.

Official Title
-----------------
Human Phototoxicity Test

Conditions
-----------------
Sunscreening Agents

Intervention / Treatment
-----------------
* Drug: Sunscreen Sport Spray (BAY987519)
* Other: Untreated Skin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be male or female between the ages of 18 and 60 inclusive; Be lightly pigmented (Fitzpatrick Skin Type I, II, III); Have read and signed the written Informed Consent Form and have completed a HIPAA Authorization Form in conformance with 45CFR Parts 160 and 164; Be in general good health as determined by the subject's medical history and in the discretion of the investigator. Exclusion Criteria: Have a visible sunburn; Have a history of sun hypersensitivity/photosensitivity or photosensitive dermatoses; Must not have a known sensitivity or allergy against any of the active and non-active ingredients of the test product. Have a history of allergies or sensitivities to cosmetics, toiletries or any dermatological products.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BAY987519<br>All subjects are patched | Drug: Sunscreen Sport Spray (BAY987519)<br>* 50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)<br>Other: Untreated Skin<br>* This site is patched without treatment as irradiated control.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of skin reactions will be evaluated using 5 point grading scale. |  | Up to 48 hours |
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

Conditions
-----------------
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type II

Intervention / Treatment
-----------------
* Drug: nateglinide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus under the treatment with pioglitazone Exclusion Criteria: Patients who cannot follow the diet therapy and/or exercise therapy Type 1 diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: nateglinide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nateglinide, pioglitazone, combination drug therapy, treatment
Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Study Overview
=================
Brief Summary
-----------------
Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.

Official Title
-----------------
Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Conditions
-----------------
Lymphoma, B-Cell

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - patient with a Diagnosis of LBDGC-SNC Exclusion criteria: immunocompromised patients patients with a history of previous or associated low-grade lymphoma patients with a history of systemic LBDGC with secondary localization to the SNC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TIM-3 and Gal-9 immunohistochemical expression | TIM-3 and Gal-9 immunohistochemical expression by tumor and microenvironment cells | 1 day |
Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

Study Overview
=================
Brief Summary
-----------------
This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.

Detailed Description
-----------------
Patients from 6 to 18 years old with asthma and receiving a treatment by salbutamol according to the usual care will be recruited. Saliva from patients will be collected using Oragen®.DNA OG-575 kit.

Official Title
-----------------
Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Salbutamol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 6-18 years Asthma: confirmed asthma symptoms (wheeze, cough, dyspnea, chest tightness) and evidence for variable airflow limitation (≥ 12% increase in post bronchodilator FEV1, or ≥ 20% decrease in FEV1 post methacholine) Spirometry prescribed for follow-up Airflow limitation: FEV1<80% and/or FEV1/FVC <80 pre-bronchodilator Exclusion Criteria: no exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Salbutamol|Measurement of bronchodilator response (BDR)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pre- and post-bronchodilator VEMS value | comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982 | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Locating other regions of the PDE4 gene that may be associated with the response to salbutamol by gene mapping (using SNP tags) | To identify other SNPs on PDE4 associated with the response (BDR) to salbutamol in childhood asthma. | Day 0 | 
| Screening other SNPs (other genes than PDE4) associated with the response to salbutamol in childhood asthma using SNP tags | To identify other genes that could be associated with the phenotype of interest (BDR) by tagging other genes. | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Salbutamol response, Phosphodiesterase 4 variant, lung function, airflow limitation
Obesity Index That Better Predict Ovarian Response

Study Overview
=================
Brief Summary
-----------------
This study is designed to assess the accuracy of Body Mass Index ,Waist Circumference ,Waist Hip Ratio or Waist Height Ratio as a predictor of ovarian response in women undergoing ICSI.

Detailed Description
-----------------
Obesity is an increasingly serious health concern worldwide, and its association with many diseases has been demonstrated. Obesity as it relates to infertility is also being studied All these studies used body mass index (BMI) to determine obesity. Although it is the most commonly used parameter to measure obesity, BMI does not provide an accurate measure of a person's body composition, including body fat. Almost all studies conducted on this subject used body mass index (BMI) as the measure of obesity; however, using only BMI might be the wrong strategy. Interestingly, some studies on the cardiovascular system found protective effects of BMI and as a result a new term, 'obesity paradox,' emerged. Later studies used waist-to-hip (W/H) ratio and wrist circumference (WC) as a measure of obesity, and showed the exact effect of body fat distribution and obesity on the cardiovascular system

Official Title
-----------------
Obesity Index That Better Predict Ovarian Response: Body Mass Index, Waist Circumference, Waist Hip Ratio, or Waist Height Ratio in Women Undergoing ICSI

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for ICSI Exclusion Criteria: Poor Responders. Poly cystic ovary syndrome. Previous ovarian surgeries. Patients with ovarian cysts patients with endometriosis women age more than 35 years

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of oocytes | number f oocytes counted at the oocyte retrieval day during ICSI | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical pregnancy rate | detection of fetal cardiac activity by transvaginal ultrasound | 7 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity Index, ICSI
Rectovaginal Fistula Repair

Study Overview
=================
Brief Summary
-----------------
This study is a prospective evaluation of quality-of-life after rectovaginal fistula repair at our institution

Detailed Description
-----------------
All patient having undergone rectovaginal fistula repair at Uppsala University Hospital 2003-2018. An invitation to join the study was sent to all patients. Those who answered were then sent Rand 36/SF36 questionnaire as a follow-up together with some general questions concerning whether the rectovaginal fistula was healed or not.

Official Title
-----------------
Rectovaginal Fistula Repair Predictors of Outcome and Results After Surgical Management

Conditions
-----------------
Fistula Vagina, Fistula;Rectal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergone RVF repair at Uppsala University Hospital 2003-2018 Exclusion Criteria: Fistula due to gender reconstructive surgery
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RVF<br>All patients having undergone repair for rectovaginal fistula | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical repair | Rate of fistula closure | Assessed on average 3 months postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health-related Quality-of-life | SF36 questionnaire | Through study completion, on average 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rectovaginal fistula, Surgical repair, Quality-of-life
Effect of Red Meat Intake on Occurrence of Serum Non-transferrin Bound Iron (NTBI)

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the effect of red meat intake on occurrence of non-transferrin bound iron (NTBI)

Detailed Description
-----------------
During Visit 1, blood samples will be collected to assess iron status. During Visit 2, after an overnight fast, participant will be given a standardized meal (rice and potatoes) with a portion of cooked beef (200 g). Blood samples will be collected right before and 2 hour after the meal for NTBI analysis. NTBI concentration before and after meal consumption will be compared.

Official Title
-----------------
Effect of Red Meat Intake on Occurrence of Serum Non-transferrin Bound Iron (NTBI)

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Beef


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Apparently healthy male volunteers (21 - 45 years old) C-reactive protein (CRP) < 5 mg/L Exclusion Criteria: Blood donation or significant blood loss (e.g. surgery) within the past 4 months Regular intake of iron and other nutrient supplements within the past 4 months Regular intake of medication except oral contraceptives Acute or recent inflammatory or infectious symptoms Chronic gastrointestinal disorders or metabolic diseases Smoking Coeliac disease or gluten-related disorders Iron deficiency anemia (Hb < 14 g/dL for males) with serum ferritin concentration < 30 ng/mL) Non-iron deficiency anemia (serum ferritin concentration within normal range (30 - 300 ng/mL for males) but low hemoglobin (< 14 g/dL for males) Iron overload conditions (serum ferritin concentration > 300 ng/mL for males) Known hereditary disorders of iron metabolism

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Beef<br>Beef topside fully cooked, 200g | Other: Beef<br>* 200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of serum non-transferrin bound iron (NTBI) after consumption of red meat | Blood samples collected 2 h after consumption of red meat will be analyzed for non-transferrin bound iron (NTBI) concentration | 2 hour post meal administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-transferrin bound iron (NTBI), Red meat, Non-transferrin bound iron (NTBI) in serum
Mapping the Areas of the Brain Associated With Language in Children With Epilepsy

Study Overview
=================
Brief Summary
-----------------
Researchers are interested in studying if magnetic resonance imaging (MRI) is practical for locating the areas of the brain associated with language in children with epilepsy. When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and water. Blood carries fuel to the brain and waste products away from the brain. As brain activity increases blood flow to and from the area of activity increases also. Patients participating in the study will be asked to perform tasks designed to test language skills while undergoing an MRI to detect areas of the brain using oxygen and receiving blood flow.

Detailed Description
-----------------
We propose to study the feasibility of utilizing MRI to perform functional mapping of language cortex in children with epilepsy. We will use 1.5 Tesla MRI to study cerebral blood flow and tissue oxygenation during cognitive activation tasks derived from previous adult studies.

Official Title
-----------------
MRI-Based Functional Language Mapping in Children With Epilepsy

Conditions
-----------------
Epilepsy, Seizures

Participation Criteria
=================
Eligibility Criteria
-----------------
Children aged 5-17 years. Partial epilepsy (localized). Ability to cooperate with task paradigms (IQ greater than 65). No cardiac pacemakers, cochlear implants, shrapnel, vascular clips, braces, or claustrophobia. No one with inability to cooperate with task paradigms.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuroimaging, Seizures, Cerebral Localization, Partial Epilepsy, Epilepsy